Abstract. Optimal control techniques are used to develop optimal strategies for chemotherapy. In particular, we investigate the qualitative differences between three different cell-kill models: logkill hypothesis (cell-kill is proportional to mass); Norton-Simon hypothesis (cell-kill is proportional to growth rate); and, Emax hypothesis (cell-kill is proportional to a saturable function of mass). For each hypothesis, an optimal drug strategy is characterized that minimizes the cancer mass and the cost (in terms of total amount of drug). The cost of the drug is nonlinearly defined in one objective functional and linearly defined in the other. Existence and uniqueness for the optimal control problems are analyzed. Each of the optimality systems, which consists of the state system coupled with the adjoint system, is characterized. Finally, numerical results show that there are qualitatively different treatment schemes for each model studied. In particular, the log-kill hypothesis requires less drug compared to the Norton-Simon hypothesis to reduce the cancer an equivalent amount over the treatment interval. Therefore, understanding the dynamics of cell-kill for specific treatments is of great importance when developing optimal treatment strategies.
criteria to be minimized. These include tumor mass and dose of drug. We give a mathematically detailed development of optimal control forms for the various growth and drug terms that are subject to different objective functionals. We also show therapeutically significant differences between the cell-kill hypotheses and their effect on treatment schedules.
We have previously developed a treatment strategy using optimal control techniques for the use of cell-cycle specific drugs such as Taxol for the reduction of breast and ovarian cancers [5] . The model included a resting phase which made it more realistic in the clinical setting. Among other things, the model showed that treating with repeated shorter periods allows more drug to be given without excess damage to the bone marrow. Similar results were also observed in [6] . Several other models where optimal control methods have been utilized in analyzing effective chemotherapeutic treatments include Swan [7, 8] and Murray [9] . Swan [7, 8] obtained feedback treatment control drug characterizations for cancer models under a quadratic performance criterion. Murray [9] has considered systems of normal and tumor cells under the hypotheses of Gompertzian and logistic growth in which he controls the rate of administration of drugs. Murray has minimized the tumor burden at the end of treatment and, in another application, the toxicity level, defined as the area under the drug concentration curve. (2.1) where N is the tumor volume, r is the growth rate of the tumor, F (N ) is the generalized growth function. For the proposed model, we allow for Gompertzian growth:
The model. Mathematically, the general form of the model under investigation is depicted by the differential equation:
The function G(N, t) describes the pharmacokinetic and pharmacodynamic effects of the drug on the system. In this study, we compare three cell-kill strategies. These include the following:
• G(N ) = δu(t)N : Skipper's log-kill (i.e., percentage kill) hypothesis,
• G(N ) = δu(t)N/(K + N ): E max model, and • G(N ) = δu(t)F (N ):
Norton-Simon hypothesis, where δ is the magnitude of the dose and the control, u(t), describes the time dependent pharmacokinetics of the drug; i.e., u(t) = 0 implies no drug effect is present and u(t) > 0 implies the amount or strength of the drug effect. We investigated the differences and similarities among the three drug effects via optimal control techniques for ordinary differential equations.
We considered two objective functionals when determining the minimum amount of drug needed to reduce or eliminate the tumor mass. One criterion considered is (2.3) where the measure of the "closeness" of the tumor mass to the desired tumor density, N d , and the cost of the control, u(t), are minimized over the class of measurable, nonnegative controls. Here, a and b are positive weight parameters. The second criterion we considered (previously used by Boldrini and Costa [10] with variations by Murray [11] and Martin and Teo [12] ) is (2.4) in which the tumor burden at the end of treatment (the first term in (2.4)) and the toxicity (the second term in (2.4)), in terms of area under the drug concentration curve, are minimized over the class of measurable, nonnegative controls.
After scaling the models using N = N/Θ, k = k/Θ, and δ = δ/Θ and dropping the bars, we have the following three state equations (which will henceforth be referred to as P1, P2, and P3, respectively), all with the same initial condition of N (0) = N 0 , where 0 < N 0 < 1 since the tumor cells have been normalized via the above change of variables:
Ultimately, we determine the unique characterization of the optimal control u(t) in the admissible control class, (2.6) such that the objective functionals J α and J β are minimized over the class of controls, U and V , respectively.
In sections 3.1-3.3, we consider the existence issues, the characterization of the optimal control, and the uniqueness concept in association with problems P1-P3 such that the objective functional (2.3) involving the nonlinear control term is minimized over the class of controls, U . In sections 4.1-4.2, we discuss the existence of an optimal control and its characterization such that it minimizes the second objective functional (2.4) subject to each of the differential equations represented in P1-P3. Also, in section 5, numerical simulations representing the control situations in relation to the two objective functionals as well as the different cell-kill hypotheses depicted in the differential equations are analyzed.
Nonlinear control.
3.1. Existence. First, the existence of the state solution to each of problems P1-P3 given an optimal control in the admissible set, U , is shown. Also, the existence of the optimal control for the state system is analyzed. Proof. We consider the following differential equations in relation to P1, P2, P3, respectively. The state variables N 1 (t), N 2 (t), and N 3 (t) represent supersolutions for problems P1, P2, and P3.
Since N (t) > 0 and ln
Since u(t) ∈ U , then, along with N 1 (t), N 2 (t) and N 3 (t) are bounded above. Via a maximum principle [13] and standard existence theory for first-order nonlinear differential equations, we obtain the existence of a solution to each of the problems P1-P3.
Next, the existence of an optimal control for the state system is analyzed. Using the fact that the solution to each state equation is bounded, the existence of an optimal control for each problem can be determined using the theory developed by Fleming and Rishel [14] .
and each of the problems P1-P3 with N (0) = N 0 , then there exists an optimal control u * associated with each problem P1-P3 such that 
We see by the representations of f, g, and h that they are continuous in t, u, and N since N (t) > 0. Also, they are each written as a linear function of the control with coefficients depending on time and the state. For the boundedness requirement, we use the bounds in the proof of Theorem 3.1 to obtain the result. Consequently,
where C 1 depends on r, d, N 0 , and T ,
and
where C 2 depends on r and d. Hence, the right-hand side of each state equation is bounded above by a sum of the control and the state. Lastly, the integrand of the objective functional is convex on U. One can consider the second partial of the integrand of the objective functional with respect to the control and find that it is positive. To obtain the necessary lower bound for the integrand, we see the
for any c > 0. Therefore, part (iv) is complete and so is the proof.
Characterization of optimal control.
Since an optimal control exists for minimizing the objective functional (2.3) subject to each of the three equations P1-P3 with the initial conditions, the necessary conditions for an optimal control for each problem are determined. For brevity, we derive the conditions using a version of Pontryagin's maximum principle for P3 [15, 16] . Then we give the optimality system, which is the state system coupled with the adjoint system, for each problem.
In order to derive the necessary conditions, we define the Lagrangian associated with J α (u) subject to P3 as
where w 1 (t) ≥ 0 is a penalty multiplier satisfying w 1 (t)u(t) = 0 at the optimal u * .
Similar definitions for hold for J α (u) subject to P1 and P2. 
with λ 3 (T ) = 0. Further, u * (t) can be represented by
Proof. The existence of the adjoint solution is found via a maximum principle satisfying [13] . Using the Lagrangian (3.8), we complete the representation for u * by analyzing the optimality condition ∂L ∂u = 0. Upon some algebraic manipulation, the representation of u * becomes
To determine an explicit expression for the optimal control, without w 1 , a standard optimality technique is utilized. The optimal control is characterized as
where
Similarly, we can find the representations for the controls associated with problems P1 and P2 that are subject to J α . The associated control for P1 is u
+ . Using this explicit representation for the control, the adjoint equation coupled with the state equation and the initial and transversality conditions form the optimality system. The optimality systems associated with each of the state equations and their associated adjoint equations are given below. We note that Optimality System 1 is associated with P1 and its adjoint, Optimality System 2 is associated with P2 and its adjoint, and Optimality System 3 is associated with P3 and its adjoint.
Optimality System 1 (OS1).
with N (0) = N 0 and λ 2 (T ) = 0.
Optimality System 3 (OS3)
.
with N (0) = N 0 and λ 3 (T ) = 0.
Uniqueness.
Here, we focus our attention on OS1 and note that similar analysis gives the uniqueness of the OS2 and OS3. The optimal control depends on the adjoint and the state variables. By proving the optimality system has a unique solution, we will argue that the optimal control is unique as well. We recognize that since the tumor mass, N (t), is bounded, then the adjoint equation (3.12) has a bounded right-hand side that is dependent on the final time T . Hence, there exists a D > 0, depending on the coefficients of the state equation and the uniform bound for
Theorem 3.4. For T sufficiently small, the solution to Optimality System 1 is unique.
Proof. We suppose that (N, λ 1 ) and (M, ψ) are two distinct solutions to OS1. Let m > 0 be chosen such that N = e mt v, M = e mt w, λ 1 = e −mt y, and ψ = e −mt z. Also,
Upon substitution of the representations for N , M , λ 1 , and ψ into the state and adjoint equations followed by simplification, we obtain the following equations:
, and z(T ) = 0. The next step is to subtract the equations corresponding to v, w, y, z. Then each of these differences are multiplied by an appropriate function and are integrated from 0 to T . We obtain the following two equations for the modified state and the adjoint:
We need to estimate several terms in order to obtain the uniqueness result. For explanation, we include one estimate below where the boundedness of the state variables and Cauchy's inequality are used:
In the estimate above, C 1 depends on the bounds of the state variables and the coefficients.
To complete this uniqueness proof, we add the two integral equations together and bounds the terms to obtain
where C 2 depends on the coefficients and the bounds of the state and the adjoint variables.
Since the variable expressions evaluated at the initial and the terminal times are nonnegative, the inequality reduces to
For the optimality system to be unique, we must choose m such that m > C2 1−r and, thus,
For this choice of m we have that T < m mr+C2 . Moreover, OS1 has a unique solution. Since the characterization of the optimal control directly depends on the state and the adjoint solutions, which are unique, then the optimal control corresponding to OS1 is unique. Similar results give uniqueness for Optimality Systems 2 and 3.
Linear control.
In this case we still consider the same three differential equations, P1-P3, subject to their initial conditions. However, in this case, we determine the existence and the characterization of an optimal control in the admissible control class, V , such that the objective functional (2.4),
is minimized over this class of controls. The goal is to find an optimal control, u * , such that
4.1. Existence. In subsection 3.1, we obtain the existence of the state solution for each problem P1-P3 given an optimal control in U . This work can be extended directly because the only change is that u(t) is bounded above by a maximum amount of drug M.
For simpler discussions, we transform the original problems P1-P3 via x = ln N . Consequently, we minimize
over the class of admissible controls, V , subject to each of the three differential equations that correspond to P1, P2, and P3, respectively. We note that k = N 0 and that the initial condition is x(0) = ln N 0 and is negative since 0 < N 0 < 1.
The theorem for the existence of an optimal control for the appropriate objective functional is stated below. Since the proof involves standard arguments, it is omitted. For further information, see [14] .
Theorem 4.1. There exists an optimal control in V that minimizes the objective functional J 1 (u) subject to (4.3), (4.4), and (4.5), respectively.
Characterization of optimal control.
Since an optimal control exists, we determine the characterization for each optimal control u(t) associated with each problem (4.3), (4.4), and (4.5) that minimizes J 1 (u). We use Pontryagin's maximum principle [17] to obtain the necessary conditions for optimality for each problem.
Theorem 4.2. Given an optimal control u * (t) and a solution, x(t) to (4.3), there exists an adjoint ψ 1 satisfying
Furthermore,
Note that this is a problem similar to Swierniak and Duda [18] . We note that ψ 1 (t) = ae x(T )−r(T −t) and a singular control could not exist. (A singular control exists when the Hamiltonian is linear in the control and the coefficient of the control is zero for some time interval.) If one were to exist, then ψ 1 (t) must equal b δ on some interval inclusive to [0,T]. This cannot occur since ψ 1 (t) would be constant only for one instant in time. Furthermore, Swierniak and Duda provide conditions for the representation of the control u * (t) in terms of the model parameters. Please see [18, 19] 
In addition,
Proof. To determine the representation for u * (t) and the differential equation associated with ψ 2 (t), we form the Hamiltonian. We note via Pontryagin's maximum principle [17] 
(T ) . This optimal control minimizes H = λ 0 bu(t)+λ(−rx(t)− u(t)δ
(k+e x(t) ) 2 ) over V . Yet, λ 0 cannot vanish for this problem because, if it did, then λ(T ) = 0 and hence λ(t) = 0 on [0, T ]. This contradicts the nontriviality of the multipliers. Therefore, without loss of generality, we let λ 0 = 1.
Consequently, we consider the following Hamiltonian, where we omit the asterisks for simplicity:
H(t, x(t), u(t), ψ 2 (t)) = bu(t) + ψ 2 (t) −rx(t) − u(t)δ (k + e x(t)
We note that from standard existence theory we obtain the existence of ψ 2 (t) solving (4.7) given that x(t) is bounded. The necessary conditions of optimality give that
We note that
is always positive on [0,T] since a > 0.
We suppose that the control is singular on
on that interval. We take the derivative with respect to time of (4.11) and obtain, after simplification,
Next, we substitute the right-hand sides of the differential equations for ψ 2 (t) and for x(t) associated with problem (4.4) and find that
Since ψ 2 (t) > 0 on [0,T] and r > 0, then
This immediately gives that x(t) is constant. Since x(t) is constant, then u(t) is constant here. We make note that with the fixed final time that H(t, x, u, ψ 2 ) is constant [20] . Since H(t, x, u, ψ 2 ) = bu + ψ 2 dx dt = bu in this case and we are minimizing H, then u(t) = 0. However, for this to occur b − ψ2δ (k+e x ) > 0, in (4.10), which contradicts our original assumption for the control to be singular. Thus, a singular control does not exist and our control is
We now determine the characterization of the optimal control to minimize J 1 (u) subject to (4.5).
Theorem 4.4. Given an optimal control u * and a corresponding solution x * (t) to (4.5), there exists an adjoint ψ 3 (t) satisfying
aδr .
(4.17)
Proof. To determine the representation for the control, we form the Hamiltonian in a similar fashion as we did in the proof of Theorem 4.3,
H(t, x(t), u(t), ψ 3 (t)) = bu(t) + ψ 3 (t)(rx(t)(u(t)δ − 1)).
As before, a solution to the adjoint exists and is given by (4.18) and a solution to the problem (4.5) is
Since x(0) < 0 and a > 0, then ψ 3 (t)x(t) < 0 on [0,T].
The necessary conditions for optimality give that
We see that
Hence, ψ 3 (t)x(t) is constant on [0,T]. This means that u * (t) must be either zero, its maximum value-M , or its singular representation on the entire interval [0,T].
Using that ψ 3 (t)x(t) is constant and that the Hamiltonian is to be minimized, we can exclude the singular case. If the control is singular, then the Hamiltonian is equal to −ψ 3 (t)x(t)r. We can see for the case, u = M , that H(t, x(t), u(t), ψ 3 (t)) < −ψ 3 (t)x(t)r. Moreover, for the case u = 0 we see that the Hamiltonian is bounded strictly above by b δ , which is the value of the Hamiltonian if the control is singular. Consequently, a singular control will not generate the minimum value for the Hamiltonian.
Therefore, the necessary conditions for optimality are
We simply need to check if the expression x(T )e x(T ) is smaller or larger than
−b
arδ . Then this determines the constant control on the interval [0,T].
Using the representation of the control in terms of the state and adjoint solutions to the transformed problems (4.3), (4.4), and (4.5), we have the associated Optimality Systems 4, 5, and 6.
Optimality System 4 (OS4).
Optimality System 5 (OS5).
Optimality System 6 (OS6).
Numerical results.
We obtain numerical solutions to each of the optimality systems using the two-point boundary value solver in Matlab [21, 22] .
OS1-OS3.
We observe several interesting differences among the three systems. First, there are significant differences between the optimal solutions of systems OS1-OS3 based on the initial tumor volume. For initial conditions near the carrying capacity (97.5% of carrying capacity), the optimal solutions for OS1 require less treatment to reduce the tumor volume the same amount as in OS2 or OS3 (Figure 5.1(A), (B) ). In particular, the optimal solution for OS1 allows for the treatment to be reduced quickly while for OS3 the treatment remains higher for a more extended period. This difference is due to the different cell-kill hypotheses of the three methods. In particular, OS1 hypothesizes that cell-kill is proportional to tumor size, thus larger tumors are effectively reduced by the drug and the optimality scheme can quickly reduce the dose needed to keep the tumor size small over the treatment interval. However, OS3 hypothesizes that cell-kill is proportional to the growth rate, which is small when the tumor is near its carrying capacity. Therefore, the optimality scheme requires more drug for a longer period of time to reduce the tumor an equivalent amount as in OS1.
For initial conditions at half the carrying capacity the differences between the optimal solutions of the three strategies are less significant ( still requires more drug early, when the growth rate was slower, to obtain the same overall cell-kill as OS1, but the differences are much smaller.
As for smaller tumors where the initial conditions are much smaller than the carrying capacity (5% of carrying capacity), the optimal solution for OS1 requires more drug later compared to the optimal solution for OS3 to have the same effect on the tumor volume ( Figure 5.1(E), (F) ). But again, the differences in this case are much less significant compared to tumors near carrying capacity.
We also consider the effects of the weights a, b, and δ in the objective function (2.3). In particular, we fix b and considered how varying a and δ affects results. (The remaining parameters are given in Table 5 .1.) In general, a smaller a, 2.5 times smaller (i.e., less weight in the objective function on minimizing the tumor volume) requires more drug (or a more effective drug) via an increase in δ (50%-60% increase) to give equivalent results ( Figure 5.2) . In general, a, b, and δ alter the quantitative but not the qualitative results.
OS4-OS6
. Systems OS4-OS6, with the linear control functional (2.4), give qualitatively different results compared to OS1-OS3. For example, OS4 and OS5 force treatment to be delayed until the later portion of the treatment interval ( Figure 5.3 ). This delay in treatment is due to the choice of the objective functional (2.4), which minimizes N at the end time T . Since (based on the Gompertz growth model) larger tumors grow much slower than smaller ones, it is more advantageous for the tumor to remain larger (and thus slower growing) for the first portion of the treatment interval and treat during the remaining portion of the treatment interval. If instead the treatment is given over the first portion of the treatment interval, then the tumor would be able to recover during the second portion of the interval at a much faster rate (since the smaller tumor after treatment has a faster growth rate) and thus not optimize the objective functional (2.4).
OS6 could only determine the length of treatment and not when treatment should be started or stopped due to the end condition being only dependent on the end time T (Figure 5.3) . However, there are also some similarities between OS1-OS3 and OS4-OS6. These include OS4, which like OS1 hypothesizes that cell-kill is proportional to the tumor volume and requires drug to be given over a shorter period (3 days) compared to the other two methods (OS5 approximately 7.5 days and OS6 approximately 4.5 days).
Conclusions.
Theoretical. There are several important differences in the objective functionals that are minimized over the two classes of controls. For the objective functional with the quadratic control (2.3), the representation for the optimal control involves both the state and the adjoint variables for all time, t. For the second objective functional (2.4), the control is explicitly dependent on the adjoint, which in turn does implicitly depend on the state, for OS4 and OS5. In OS6, the control is dependent only on the final time and the evaluation of the state at the final time.
Within OS1-OS3, the existence, uniqueness, and characterization of the optimal control are easier to obtain because of the nonlinear control. The biological validity of the quadratic cost term has been debated [7] . However, its use in order to incorporate the nonlinear flavor of the problem has given results that are qualitatively significant. For OS4-OS6, an interesting component is the bang-bang structure of the optimal controls. An intriguing difference occurs in OS6 in which the optimal control depends on the length of the treatment. Once this is known, the control will either be given at the maximum or the minimum level. A future problem relating to OS6 could involve the minimization of the time of treatment in conjunction with the minimization of the drug needed.
The mathematical significance of these problems lies in the similarities and differences of the construction of the controls. Basic concepts using a Lagrangian or Hamiltonian are needed in each. Yet, the possibility of singular controls in section 4 required more explorations of the control representations. In this investigation, the strategies employed in both the nonlinear and the linear control settings attempt to qualitatively answer the questions relating to the appropriate drug treatment to impose under the given three hypotheses of cell-kill.
Clinical. The most important clinical question that this study addresses is, When can drug treatment be reduced to reduce toxicity? If the log-kill hypothesis is used, then the optimal control systems suggest that treatment can be given for a shorter period of time relative to the Norton-Simon hypothesis. However, the consequence of choosing the incorrect hypothesis is to either under-or over-treat the patient, causing ineffective reduction of the tumor or toxicity, respectively. Therefore, more studies are needed to determine the specific dynamics of various drugs on tumors relative to these (or other) cell-kill hypotheses.
We also observe qualitatively different treatment strategies based on the use of different objective functionals. These differences show the importance of defining an objective functional that most accurately reflects the toxicities of a particular drug along with the objective of the treatment strategy, e.g., reduce the tumor mass at the end of the treatment interval, reduce the overall tumor burden over the treatment interval, or some other clinically relevant criteria.
